DE69130912T2 - Antikörperherstellung - Google Patents
AntikörperherstellungInfo
- Publication number
- DE69130912T2 DE69130912T2 DE69130912T DE69130912T DE69130912T2 DE 69130912 T2 DE69130912 T2 DE 69130912T2 DE 69130912 T DE69130912 T DE 69130912T DE 69130912 T DE69130912 T DE 69130912T DE 69130912 T2 DE69130912 T2 DE 69130912T2
- Authority
- DE
- Germany
- Prior art keywords
- antibody
- line
- antibody production
- expressing
- cho cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB909022543A GB9022543D0 (en) | 1990-10-17 | 1990-10-17 | Antibody production |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69130912D1 DE69130912D1 (de) | 1999-04-01 |
DE69130912T2 true DE69130912T2 (de) | 1999-09-02 |
Family
ID=10683862
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69130912T Expired - Fee Related DE69130912T2 (de) | 1990-10-17 | 1991-10-17 | Antikörperherstellung |
DE69133472T Expired - Lifetime DE69133472T2 (de) | 1990-10-17 | 1991-10-17 | Antikörper und ihre therapeutische Verwendung |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69133472T Expired - Lifetime DE69133472T2 (de) | 1990-10-17 | 1991-10-17 | Antikörper und ihre therapeutische Verwendung |
Country Status (13)
Country | Link |
---|---|
US (7) | US5545403A (de) |
EP (5) | EP1247865B1 (de) |
JP (1) | JPH0690752A (de) |
AT (2) | ATE176926T1 (de) |
CA (1) | CA2053585C (de) |
DE (2) | DE69130912T2 (de) |
DK (1) | DK0481790T3 (de) |
ES (2) | ES2131507T3 (de) |
GB (1) | GB9022543D0 (de) |
GR (1) | GR3030289T3 (de) |
IE (1) | IE913558A1 (de) |
NZ (1) | NZ240249A (de) |
ZA (1) | ZA918248B (de) |
Families Citing this family (156)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6893625B1 (en) * | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US7247475B2 (en) * | 1989-07-28 | 2007-07-24 | Wyeth | Method for producing monoclonal antibodies |
US6475787B1 (en) | 1989-07-28 | 2002-11-05 | Wyeth | Method for producing monoclonal antibodies |
GB9020282D0 (en) * | 1990-09-17 | 1990-10-31 | Gorman Scott D | Altered antibodies and their preparation |
GB9022543D0 (en) * | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
US6800738B1 (en) * | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
GB9122820D0 (en) * | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
GB9125768D0 (en) * | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
DE4314556A1 (de) * | 1993-05-04 | 1994-11-10 | Behringwerke Ag | Modifizierte Antikörperenzymkonjugate und Fusionsproteine sowie ihre Anwendung zur tumorselektiven Therapie |
GB9424449D0 (en) * | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
ATE395422T1 (de) | 1995-06-07 | 2008-05-15 | Sanofi Pasteur Ltd | Chimäre antikörper zur abgabe von antigenen an selektierte zellen des immunsystems |
US6328962B2 (en) | 1995-06-07 | 2001-12-11 | Aventis Pasteur Limited | Method for delivery of antigens to selected cells of the immune system using chimeric antibodies |
JP4503706B2 (ja) | 1996-06-07 | 2010-07-14 | ポニアード ファーマシューティカルズ,インコーポレイティド | グリコシル化が改質されたヒト化抗体 |
US6475725B1 (en) | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
US20020029391A1 (en) * | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
MY133346A (en) * | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
US20020102208A1 (en) * | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
US7829085B2 (en) | 1999-07-14 | 2010-11-09 | Life Sciences Research Partners Vzw | Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII |
EP2330092A3 (de) * | 2000-02-01 | 2012-07-25 | Stevia APS | Arzneimittel enthaltend Steviol oder Isosteviol zur Behandlung des Insulinunabhängigen Diabetes Mellitus, Bluthochdruck und/oder des metabolischen Syndroms |
US6573096B1 (en) * | 2000-04-01 | 2003-06-03 | The Research Foundation At State University Of New York | Compositions and methods for inhibition of cancer invasion and angiogenesis |
EP1311269B1 (de) | 2000-08-04 | 2012-02-29 | DMI Biosciences, Inc. | Verfahren zur verwendung von diketopiperazinen und zusammensetzungen, die diese enthalten |
WO2002062850A2 (en) * | 2001-02-02 | 2002-08-15 | Millennium Pharmaceuticals, Inc. | Hybrid antibodies and uses thereof |
US6972324B2 (en) | 2001-05-18 | 2005-12-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Antibodies specific for CD44v6 |
GB0123098D0 (en) * | 2001-09-26 | 2001-11-14 | Lonza Biologics Plc | Use of aminoglycoside resistance gene |
US7092957B2 (en) * | 2002-01-18 | 2006-08-15 | Boundary Solutions Incorporated | Computerized national online parcel-level map data portal |
US7217796B2 (en) | 2002-05-24 | 2007-05-15 | Schering Corporation | Neutralizing human anti-IGFR antibody |
JP4836451B2 (ja) | 2002-07-18 | 2011-12-14 | メルス ベー ヴェー | 抗体混合物の組換え生産 |
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
DK1571970T3 (da) * | 2002-10-02 | 2011-11-28 | Dmi Biosciences Inc | Diagnose og monitorering af sygdomme |
AU2003274011B2 (en) | 2002-10-15 | 2010-03-04 | Intercell Ag | Nucleic acids coding for adhesion factor of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof |
PT2301965E (pt) | 2002-10-16 | 2015-05-20 | Purdue Pharma Lp | Anticorpos que se ligam a ca 125/0722p associado a células e métodos para a sua utilização |
SI1583830T1 (sl) | 2003-01-07 | 2006-12-31 | Symphogen As | Postopek za pripravo rekombinantnih poliklonskih proteinov |
US7790399B2 (en) | 2003-04-03 | 2010-09-07 | Laboratoire Francais du Fractionnement et des Biotechnolgies (LFB) | Preparation of human, humanized or chimaeric antibodies or polypeptides having different binding profiles to Fcgamma receptors |
US8012681B2 (en) | 2003-05-13 | 2011-09-06 | Novartis Vaccines And Diagnostics, Inc. | Methods of modulating metastasis and skeletal related events resulting from metastases |
JP4422430B2 (ja) | 2003-05-14 | 2010-02-24 | 帝國製薬株式会社 | エストロゲン及び/又はプロゲストゲン含有外用貼付剤 |
ES2572975T3 (es) | 2003-05-15 | 2016-06-03 | Ampio Pharmaceuticals, Inc. | Tratamiento de enfermedades mediadas por los linfocitos T |
WO2004106375A1 (en) | 2003-05-30 | 2004-12-09 | Merus Biopharmaceuticals B.V. I.O. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
EP1706079B1 (de) | 2003-08-14 | 2013-02-20 | ThromboGenics N.V. | Antikörper gegen faktor viii mit modifizierter glykosilierung in der variablen region |
EP1680141B8 (de) | 2003-11-04 | 2011-01-12 | Novartis Vaccines and Diagnostics, Inc. | Verfahren zur behandlung von soliden tumoren mit expression des cd40-zelloberflächen-antigens |
ATE447412T1 (de) | 2003-11-04 | 2009-11-15 | Novartis Vaccines & Diagnostic | Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren |
EP1844815B1 (de) | 2003-11-04 | 2011-09-14 | Novartis Vaccines and Diagnostics, Inc. | Kombinationstherapie von anti-CD20 und anti-CD40 Antikörpern zur Behandlung von B-Zell-bedingtem Krebs |
US20070218060A1 (en) | 2003-11-04 | 2007-09-20 | Chiron Corporation | Use of Antagonist Anti-Cd40 Monoclonal Antibodies for Treatment of Multiple Myeloma |
JP4765037B2 (ja) | 2003-11-04 | 2011-09-07 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 慢性リンパ球性白血病の処置のためのアンタゴニスト抗cd40モノクローナル抗体の使用 |
AU2005205412B2 (en) | 2004-01-20 | 2011-08-11 | Merus N.V. | Mixtures of binding proteins |
WO2006125640A2 (en) * | 2005-05-24 | 2006-11-30 | Morphosys Ag | Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38 |
US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
CA2555185C (en) | 2004-02-06 | 2020-03-24 | Morphosys Ag | Anti-cd38 human antibodies and uses therefor |
WO2006020114A2 (en) | 2004-08-04 | 2006-02-23 | Applied Molecular Evolution, Inc. | Variant fc regions |
ES2555355T3 (es) | 2004-09-03 | 2015-12-30 | Genentech, Inc. | Antagonistas anti-beta7 humanizados y utilizaciones para los mismos |
US8137907B2 (en) | 2005-01-03 | 2012-03-20 | Cold Spring Harbor Laboratory | Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof |
US7589182B1 (en) | 2005-01-07 | 2009-09-15 | Los Alamos National Security, Llc | Anti-sulfotyrosine antibodies |
US8165517B2 (en) * | 2005-01-19 | 2012-04-24 | The Trustees Of The University Of Pennsylvania | Methods for identifying inhibitors of vascular injury |
CA2597924C (en) * | 2005-02-15 | 2018-10-02 | Duke University | Anti-cd19 antibodies and uses in oncology |
US8444973B2 (en) | 2005-02-15 | 2013-05-21 | Duke University | Anti-CD19 antibodies and uses in B cell disorders |
US7595380B2 (en) | 2005-04-27 | 2009-09-29 | Tripath Imaging, Inc. | Monoclonal antibodies and methods for their use in the detection of cervical disease |
WO2006121852A2 (en) * | 2005-05-05 | 2006-11-16 | Duke University | Anti-cd19 antibody therapy for autoimmune disease |
EP2312315A1 (de) | 2005-05-18 | 2011-04-20 | Novartis AG | Verfahren zur Diagnose und Behandlung von Krankheiten mit einer autoimmunen und/oder entzündlichen Komponente |
EP1896587A2 (de) | 2005-05-31 | 2008-03-12 | Cold Spring Harbor Laboratory | Verfahren zur mikro-rna-herstellung |
EP1904101A4 (de) * | 2005-06-08 | 2011-06-15 | Univ Duke | Anti-cd19-antikörper-therapie für transplantation |
AU2006301446B2 (en) | 2005-10-12 | 2012-06-07 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
WO2007046439A1 (ja) * | 2005-10-18 | 2007-04-26 | National Institute Of Agrobiological Sciences | 抗体を産生するトランスジェニックカイコとその製造方法 |
US7632498B2 (en) | 2005-12-19 | 2009-12-15 | Tripath Imaging, Inc. | MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease |
EP1806365A1 (de) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antikörper spezifisch für Fibroblasten-Aktivierungsprotein und Immunokonjugaten, die diese Antikörper enthalten |
US20080014203A1 (en) * | 2006-04-11 | 2008-01-17 | Silke Hansen | Antibodies against insulin-like growth factor I receptor and uses thereof |
JP2009541208A (ja) | 2006-04-13 | 2009-11-26 | ノバルティス・バクシーンズ・アンド・ダイアグノスティクス・インコーポレイテッド | がんを処置し、診断しもしくは検出する方法 |
NZ571757A (en) | 2006-04-21 | 2012-01-12 | Novartis Ag | Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer |
WO2007127936A2 (en) | 2006-04-27 | 2007-11-08 | Pikamab, Inc. | Methods and compositions for antibody therapy |
WO2008022152A2 (en) | 2006-08-14 | 2008-02-21 | Xencor, Inc. | Optimized antibodies that target cd19 |
ATE551071T1 (de) | 2006-09-08 | 2012-04-15 | Medimmune Llc | Humanisierte anti-cd19-antikörper und ihre verwendung für die behandlung von krebs, transplantationen und autoimmunerkrankungen |
MY161866A (en) | 2006-09-13 | 2017-05-15 | Abbvie Inc | Cell culture improvements |
US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
WO2008043018A1 (en) | 2006-10-04 | 2008-04-10 | Dana-Farber Cancer Institute, Inc. | Tumor immunity |
JP2010521180A (ja) | 2007-03-14 | 2010-06-24 | ノバルティス アーゲー | 癌を処置、診断または検出するためのapcdd1阻害剤 |
SI2152872T1 (sl) | 2007-05-25 | 2011-01-31 | Symphogen As | Postopek za pripravo rekombinantnega poliklonskega proteina |
EP2195009B1 (de) | 2007-09-26 | 2014-07-30 | Oregon Health and Science University | Zyklische undekapeptide und derivate als therapien für multiple sklerose |
EP2300011A4 (de) | 2008-05-27 | 2012-06-20 | Dmi Life Sciences Inc | Therapeutische verfahren und verbindungen |
DK2349341T3 (da) * | 2008-10-15 | 2014-01-06 | Baxter Int | Pegylering af rekombinante blodkoagulationsfaktorer i nærvær af bundne antistoffer |
EP2403880A1 (de) | 2009-03-05 | 2012-01-11 | Tripath Imaging, Inc. | Monoklonale antikörper gegen matrixmetalloproteinase-7 (mmp-7) und verfahren zu ihrer verwendung beim nachweis von eierstockkrebs |
AU2010221188A1 (en) | 2009-03-06 | 2011-10-20 | Tripath Imaging, Inc. | Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer |
MX347291B (es) | 2009-03-20 | 2017-04-17 | Amgen Inc | Inmunoglobulinas portadoras y usos de las mismas. |
MX342907B (es) | 2009-05-13 | 2016-10-17 | Genzyme Corp * | El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus. |
CA2939492C (en) | 2009-05-13 | 2019-03-19 | Genzyme Corporation | Anti-human cd52 immunoglobulins |
JP4525863B1 (ja) * | 2009-06-05 | 2010-08-18 | 東洋紡績株式会社 | 高生産性細胞の樹立のための発現ベクター及び高生産性細胞 |
WO2011028390A1 (en) | 2009-08-24 | 2011-03-10 | St. Jude Children's Research Hospital | Compositions and methods for potentiating interleukin-35 |
TW201129379A (en) | 2009-11-20 | 2011-09-01 | Amgen Inc | Anti-Orai1 antigen binding proteins and uses thereof |
WO2011063198A2 (en) | 2009-11-20 | 2011-05-26 | St. Jude Children's Research Hospital | Methods and compositions for modulating the activity of the interleukin-35 receptor complex |
EP2325322A1 (de) * | 2009-11-23 | 2011-05-25 | 4-Antibody AG | Retrovirusvektorpartikel und Verfahren zu deren Erzeugung und Verwendung |
US8383793B2 (en) | 2010-04-15 | 2013-02-26 | St. Jude Children's Research Hospital | Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors |
US20140072983A1 (en) | 2010-08-10 | 2014-03-13 | Amgen Inc. | Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies |
US8507496B2 (en) | 2010-09-07 | 2013-08-13 | Dmi Acquisition Corp. | Treatment of diseases |
EA201370076A1 (ru) | 2010-09-22 | 2013-08-30 | Амген Инк. | Иммуноглобулины-переносчики и их применение |
US9005907B2 (en) | 2010-10-01 | 2015-04-14 | St. Jude Children's Research Hospital | Methods and compositions for typing molecular subgroups of medulloblastoma |
WO2012075111A1 (en) | 2010-11-30 | 2012-06-07 | Novartis Ag | Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers |
JP2012125197A (ja) * | 2010-12-16 | 2012-07-05 | Kyowa Hakko Kirin Co Ltd | タンパク質の生産方法 |
KR20140009311A (ko) | 2011-01-18 | 2014-01-22 | 암젠 인크 | Nav1.7 넉아웃 마우스 및 이의 용도 |
US20140157443A1 (en) | 2011-04-14 | 2014-06-05 | St. Jude Children's Research Hospital | Methods and compositions for detecting and modulating a novel mtor complex |
WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
KR20140035967A (ko) | 2011-05-26 | 2014-03-24 | 유니버시티 오브 워싱톤 | 세포 및 유전자에 기반한 심장 기능을 개선하는 방법 |
RS55822B1 (sr) | 2011-09-30 | 2017-08-31 | Dana-Farber Cancer Institute Inc | Terapijski peptidi |
EP3721884A1 (de) | 2011-10-10 | 2020-10-14 | Ampio Pharmaceuticals, Inc. | Behandlung degenerativer gelenkerkrankung mit da-dkp (= aspartly-alanyl-diketopiperazin) |
US9925300B2 (en) | 2011-10-10 | 2018-03-27 | Ampio Pharmaceuticals, Inc. | Implantable medical devices with increased immune tolerance, and methods for making and implanting |
WO2013063413A1 (en) | 2011-10-28 | 2013-05-02 | Ampio Pharmaceuticals, Inc. | Treatment of rhinitis |
EP3559049A4 (de) | 2011-10-28 | 2019-12-04 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptidkonstrukte und anwendungen davon |
WO2013126813A1 (en) | 2012-02-22 | 2013-08-29 | Amgen Inc. | Autologous mammalian models derived from induced pluripotent stem cells and related methods |
US9895437B2 (en) | 2012-04-18 | 2018-02-20 | Valneva Austria Gmbh | Aluminum compounds for use in therapeutics and vaccines |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
PT2838917T (pt) | 2012-04-20 | 2019-09-12 | Merus Nv | Métodos e meios para a produção de moléculas similares a ig heterodiméricas |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
EP2869845B1 (de) | 2012-07-06 | 2019-08-28 | Genmab B.V. | Dimerprotein mit dreifacher mutation |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
US9206390B2 (en) | 2012-09-02 | 2015-12-08 | Abbvie, Inc. | Methods to control protein heterogeneity |
DK2900694T3 (en) | 2012-09-27 | 2018-11-19 | Merus Nv | BISPECIFIC IGG ANTIBODIES AS T-CELL ACTIVATORS |
EP2722341B1 (de) | 2012-10-22 | 2017-12-06 | Fountain Biopharma Inc. | Antikörper gegen Interleukin-6 und Verwendungen davon |
WO2014143205A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
CA2906864A1 (en) | 2013-03-15 | 2014-09-18 | Ampio Pharmaceuticals, Inc. | Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same |
US10745483B2 (en) | 2013-03-15 | 2020-08-18 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
AR095199A1 (es) | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
ES2672989T3 (es) | 2013-03-15 | 2018-06-19 | Sutter Bay Hospitals | FALZ para su uso como diana para terapias para tratar el cáncer |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
AU2013388126B2 (en) | 2013-04-29 | 2019-03-07 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2b |
EP3052640A2 (de) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Verwendung von metallionen zur modulation von proteinglykosylierungsprofilen rekombinanter proteine |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
MX371187B (es) | 2013-12-06 | 2020-01-22 | Dana Farber Cancer Inst Inc | Péptidos terapéuticos. |
NZ724013A (en) | 2014-02-28 | 2019-11-29 | Merus Nv | Antibodies that bind egfr and erbb3 |
WO2015130173A1 (en) | 2014-02-28 | 2015-09-03 | Merus B.V. | Antibody that binds erbb-2 and erbb-3 |
AU2015229009B2 (en) | 2014-03-14 | 2019-08-22 | Dana-Farber Cancer Institute, Inc. | Vaccine compositions and methods for restoring NKG2D pathway function against cancers |
UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
AU2015264114A1 (en) | 2014-05-21 | 2016-11-03 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer with anti BiP or anti MICA antibodies |
JP6723222B2 (ja) | 2014-08-18 | 2020-07-15 | アンピオ ファーマシューティカルズ,インコーポレイテッド | 関節病態の治療 |
ES2962385T3 (es) | 2014-10-15 | 2024-03-18 | Amgen Inc | Elementos promotores y reguladores para mejorar la expresión de genes heterólogos en células hospederas |
KR102639037B1 (ko) | 2014-10-29 | 2024-02-20 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 인터페론 α2b 변이체 |
WO2016209969A1 (en) | 2015-06-22 | 2016-12-29 | Ampio Pharmaceuticals, Inc. | Use of low molecular weight fractions of human serum albumin in treating diseases |
AU2016293942B2 (en) | 2015-07-10 | 2022-06-16 | Merus N.V. | Human CD3 binding antibody |
KR20180100305A (ko) | 2015-10-23 | 2018-09-10 | 메뤼스 엔.페. | 암 성장을 억제하는 결합 분자 |
CA3058343A1 (en) | 2017-03-31 | 2018-10-04 | Merus N.V. | Erbb-2 and erbb-3 binding bispecific antibodies for use in the treatment of cells that have an nrg1 fusion gene |
BR112020002695A2 (pt) | 2017-08-09 | 2020-08-25 | Merus N.V. | anticorpos que se ligam à egfr e cmet |
JP7230819B2 (ja) | 2017-10-06 | 2023-03-01 | 小野薬品工業株式会社 | 二重特異性抗体 |
TWI804572B (zh) | 2018-02-09 | 2023-06-11 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
TW202102544A (zh) | 2019-04-04 | 2021-01-16 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
TWI809286B (zh) | 2019-07-05 | 2023-07-21 | 日商小野藥品工業股份有限公司 | 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療 |
JP6856183B1 (ja) | 2019-07-30 | 2021-04-07 | 小野薬品工業株式会社 | 二重特異性抗体 |
TW202120550A (zh) | 2019-08-08 | 2021-06-01 | 日商小野藥品工業股份有限公司 | 雙特異性蛋白質 |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1A (en) * | 1836-07-13 | John Ruggles | Locomotive steam-engine for rail and other roads | |
US4205126A (en) * | 1978-01-01 | 1980-05-27 | Cartaya Oscar A | Serum-free cell culture media |
US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
NZ198445A (en) * | 1980-09-25 | 1984-05-31 | Genentech Inc | Production of human fibroblast interferon by recombinant dna technology |
US4608337A (en) * | 1980-11-07 | 1986-08-26 | The Wistar Institute | Human hybridomas and the production of human monoclonal antibodies by human hybridomas |
US4456748A (en) * | 1981-02-23 | 1984-06-26 | Genentech, Inc. | Hybrid human leukocyte interferons |
US4657866A (en) * | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4767704A (en) * | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
JPS6147500A (ja) * | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
US5807715A (en) * | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
DE3688418T2 (de) * | 1985-02-13 | 1993-08-26 | Scios Nova Inc | Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen. |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
CA1297434C (en) * | 1986-04-14 | 1992-03-17 | Kenji Murakami | Method of producing peptides, recombinant plasmid for use in the same and animal cells transformed with the same |
US5045468A (en) * | 1986-12-12 | 1991-09-03 | Cell Enterprises, Inc. | Protein-free culture medium which promotes hybridoma growth |
IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
DE3871206D1 (de) * | 1987-03-24 | 1992-06-25 | Grace W R & Co | Basisnaehrmedium fuer eine zellkultur. |
US5001065A (en) * | 1987-05-27 | 1991-03-19 | Cetus Corporation | Human cell line and triomas, antibodies, and transformants derived therefrom |
CA1341235C (en) | 1987-07-24 | 2001-05-22 | Randy R. Robinson | Modular assembly of antibody genes, antibodies prepared thereby and use |
GB8719963D0 (en) * | 1987-08-24 | 1987-09-30 | Cattaneo A | Recombinant dna products |
GB8720833D0 (en) * | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US5336603A (en) * | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
GB8800077D0 (en) * | 1988-01-05 | 1988-02-10 | Ciba Geigy Ag | Novel chimeric antibodies |
DE3801236A1 (de) * | 1988-01-18 | 1989-07-27 | Boehringer Mannheim Gmbh | Pentosansulfat-medium |
PT89484B (pt) * | 1988-01-22 | 1994-03-31 | Gen Hospital Corp | Genes clonados codificadores de proteinas de fusao ig-cd4 e sua utilizacao |
US5846534A (en) * | 1988-02-12 | 1998-12-08 | British Technology Group Limited | Antibodies to the antigen campath-1 |
ATE95068T1 (de) | 1988-02-12 | 1993-10-15 | British Tech Group | Modifizierte antikoerper. |
US6010902A (en) * | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
US4975369A (en) * | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
EP0365209A3 (de) * | 1988-10-17 | 1990-07-25 | Becton, Dickinson and Company | Aminosäuresequenz des Anti-leu 3a |
FR2639232A1 (fr) * | 1988-10-21 | 1990-05-25 | Sanofi Sa | Medicaments contenant une interleukine-2 glycosylee |
US5417970A (en) * | 1988-10-21 | 1995-05-23 | Sanofi | Drugs containing a glycosylated interleukin-2 |
US4929706A (en) * | 1988-11-02 | 1990-05-29 | W. R. Grace & Co.-Conn. | Cell growth enhancers and/or antibody production stimulators comprising chemically modified hydrophilic polyurea-urethane prepolymers and polymers |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
JP2751325B2 (ja) * | 1989-02-22 | 1998-05-18 | 三菱化学株式会社 | 蛋白質の産生方法 |
US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5098833A (en) * | 1989-02-23 | 1992-03-24 | Genentech, Inc. | DNA sequence encoding a functional domain of a lymphocyte homing receptor |
GB8905669D0 (en) * | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
US6291158B1 (en) * | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
US5081235A (en) * | 1989-07-26 | 1992-01-14 | City Of Hope | Chimeric anti-cea antibody |
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
GB9014932D0 (en) * | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
US5122469A (en) * | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
GB9022543D0 (en) * | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
GB9022545D0 (en) * | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
ATE170559T1 (de) * | 1991-05-31 | 1998-09-15 | Genentech Inc | Behandlung der hiv-assoziierten immun- thrombopenie purpura |
IE922287A1 (en) * | 1991-07-15 | 1993-01-27 | Wellcome Found | Production of antibodies |
GB9115364D0 (en) * | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
DK0610447T3 (da) * | 1991-10-15 | 1999-08-23 | Btg Int Ltd | CDw52-specifikt antistof til behandling af T-cellemedieret inflammation af leddene |
GB9125768D0 (en) * | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
US5483047A (en) * | 1994-03-15 | 1996-01-09 | Inter Bold | Automated teller machine |
US7775598B2 (en) * | 2007-07-03 | 2010-08-17 | Keiper Gmbh & Co. Kg | Fitting for a vehicle seat |
-
1990
- 1990-10-17 GB GB909022543A patent/GB9022543D0/en active Pending
-
1991
- 1991-10-16 NZ NZ240249A patent/NZ240249A/en not_active IP Right Cessation
- 1991-10-16 ZA ZA9118248A patent/ZA918248B/xx unknown
- 1991-10-16 IE IE355891A patent/IE913558A1/en not_active Application Discontinuation
- 1991-10-16 CA CA002053585A patent/CA2053585C/en not_active Expired - Lifetime
- 1991-10-17 ES ES91309595T patent/ES2131507T3/es not_active Expired - Lifetime
- 1991-10-17 EP EP02076251A patent/EP1247865B1/de not_active Revoked
- 1991-10-17 AT AT91309595T patent/ATE176926T1/de not_active IP Right Cessation
- 1991-10-17 JP JP3333868A patent/JPH0690752A/ja active Pending
- 1991-10-17 DK DK91309595T patent/DK0481790T3/da active
- 1991-10-17 EP EP04077314A patent/EP1484402A3/de not_active Ceased
- 1991-10-17 DE DE69130912T patent/DE69130912T2/de not_active Expired - Fee Related
- 1991-10-17 ES ES02076251T patent/ES2242822T3/es not_active Expired - Lifetime
- 1991-10-17 DE DE69133472T patent/DE69133472T2/de not_active Expired - Lifetime
- 1991-10-17 EP EP97201842A patent/EP0822255A3/de not_active Withdrawn
- 1991-10-17 EP EP91309595A patent/EP0481790B1/de not_active Revoked
- 1991-10-17 AT AT02076251T patent/ATE297988T1/de not_active IP Right Cessation
- 1991-10-17 EP EP08154434A patent/EP1950301A3/de not_active Withdrawn
-
1993
- 1993-11-23 US US08/155,864 patent/US5545403A/en not_active Expired - Lifetime
-
1994
- 1994-11-03 US US08/335,401 patent/US5545405A/en not_active Expired - Lifetime
- 1994-11-03 US US08/335,400 patent/US5545404A/en not_active Expired - Lifetime
-
1999
- 1999-05-20 GR GR990401375T patent/GR3030289T3/el unknown
-
2002
- 2002-05-16 US US10/145,712 patent/US20020182208A1/en not_active Abandoned
- 2002-05-16 US US10/145,992 patent/US20030035799A1/en not_active Abandoned
-
2004
- 2004-01-28 US US10/765,067 patent/US20040228857A1/en not_active Abandoned
-
2008
- 2008-07-28 US US12/122,123 patent/US20080279852A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69130912T2 (de) | Antikörperherstellung | |
DK172089A (da) | 1,3-dioxolanderivater samt fremgangsmaade til fremstilling deraf | |
ATE121066T1 (de) | Verfahren zur herstellung von 6,12-dihydro-6- hydroxy-cannabidiol und dessen anwendung zur herstellung von trans-delta-9- tetrahydrocannabinol. | |
NO20016226D0 (no) | Fremgangsmåte for fremstilling av substituerte formamider | |
ATE157093T1 (de) | Rs-thioctsäure mit neuartiger morphologie | |
ATE50265T1 (de) | Herstellung von 7-halo-7-deoxylincomycinen. | |
ES2086065T3 (es) | Preparacion de tetrahidropiridinas sustituidas. | |
DK0407212T3 (da) | Enantioselektiv syntese af antifolater | |
BR9401156A (pt) | Processo para a produção de um composto de alcoxiiminoacetamida | |
NO913078L (no) | Oekt proteinproduksjon i dyr. | |
ATE312193T1 (de) | Microbiologische herstellung von l-ascorbinsäure | |
ES2128332T3 (es) | Metodo para la produccion de la 2-amino-6-halogenopurina y sintesis de un intermediario. | |
DE376516T1 (de) | Verfahren zur herstellung von nabumeton. | |
BR9304237A (pt) | Processo para a preparaçao de PH3C(B(C6F5)4) | |
DK0441708T3 (da) | Fremgangsmåde til fremstilling af terpenketoner | |
DE69115090D1 (de) | Verfahren zur Herstellung von Fluormethyl-substituierten Pyridin-carbodithioaten. | |
ES2089176T3 (es) | Procedimiento para la preparacion de carboditioatos de piperidina fluorometil-sustituidos. | |
PT92096A (pt) | Processo de fabrico de objectos moldados, de uma materia-prima de fibras fluidizada | |
DK0704438T3 (da) | Fremgangsmåde til fremstilling af 2-cyaniminothiazolidin | |
ATE162511T1 (de) | Verfahren zur herstellung von 4,5- difluorbenzaldehyden | |
DK0439058T3 (da) | Acycliske terpener | |
ES2080286T3 (es) | Procedimiento para la preparacion de piridinadicarboxilatos sustituidos con fluorometilo. | |
DK36689A (da) | Fremgangsmaade til fremstilling af et 16-methoxy-16-methyl-prostaglandin e1-derivat, samt ved fremgangsmaaden anvendelige mellemprodukter | |
DK93884A (da) | Fremgangsmaade til fremstilling af 1,5-dibeskyttede-1,5,10-triazadecaner, mellemprodukter derfor samt disses fremstilling | |
ES2053857T3 (es) | Un procedimiento para producir una cis-hidroxitrans-fenociclopentilamina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent | ||
8339 | Ceased/non-payment of the annual fee |